How should schemes react to stagnating life expectancy?

Life expectancy in the UK has flatlined in the past two years. Is this a blip, or will we see a return to the fast improvements seen at the start of the century? Hugh Nolan, director at Spence & Partners, discusses how trustees can manage scheme funding despite this uncertainty.